◼ Archived
Business
FDA pauses Regenxbio gene therapy trial again due to safety concerns
The FDA has halted Regenxbio's gene therapy trial for Hunter Syndrome for the second time, sending the company's stock tumbling.
Hunter Syndrome
2 independently detected trends connected to this subject, with the latest coverage first.
What Archynetys tracks about Hunter Syndrome
This hub groups 2 separate news trends connected to Hunter Syndrome, spanning June 22, 2026 through August 24, 2026. Each event page combines source coverage, attention velocity and a time-stamped explanation instead of treating every headline as a separate story.
The record below represents 19 article observations and 18 source signals, led by Business coverage. Use it to compare how individual events emerged, spread and changed over time.
◼ Archived
Business
🔮 fades ✓
Exclusive | FDA Will Reverse Rejection of Third Rare-Disease Drug, Regenxbio Says
The FDA is reversing its rejection of Regenxbio's gene therapy for Hunter syndrome, marking the third such reversal for rare-disease drugs.